Get Premium to unlock powerful stock data
NAS:OPNT (USA)   Healthcare » Biotechnology
Opiant Pharmaceuticals Inc logo

Opiant Pharmaceuticals Inc $ 22.71 -1.2 (-5.02%)

On watch
Volume:
38,766
Avg Vol (1m):
66,632
Market Cap $:
99.92 Mil
Enterprise Value $:
76.64 Mil
PE Ratio:
At Loss
PB Ratio:
2.71
Warning! GuruFocus has detected 3 Severe warning signs with OPNT. Click here to check it out.
Also Trade In: Germany
EMBED
5D 3M YTD 1Y 3Y 5Y 10Y All 10Y -%
Above Low: +NaN%
Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Opiant Pharmaceuticals Inc () from 2007 to Oct 26 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Opiant Pharmaceuticals stock (OPNT) PE ratio as of Oct 26 2021 is 0. More Details

Opiant Pharmaceuticals PE Ratio (TTM) Chart

EMBED

Opiant Pharmaceuticals PE Ratio (TTM) Historical Data

Total 1262
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Opiant Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-10-26At Loss 2021-08-24At Loss
2021-10-25At Loss 2021-08-23At Loss
2021-10-22At Loss 2021-08-20At Loss
2021-10-21At Loss 2021-08-19At Loss
2021-10-20At Loss 2021-08-18At Loss
2021-10-19At Loss 2021-08-17At Loss
2021-10-18At Loss 2021-08-16At Loss
2021-10-15At Loss 2021-08-13At Loss
2021-10-14At Loss 2021-08-12At Loss
2021-10-13At Loss 2021-08-11At Loss
2021-10-12At Loss 2021-08-10At Loss
2021-10-11At Loss 2021-08-09At Loss
2021-10-08At Loss 2021-08-06At Loss
2021-10-07At Loss 2021-08-05At Loss
2021-10-06At Loss 2021-08-04At Loss
2021-10-05At Loss 2021-08-03At Loss
2021-10-04At Loss 2021-08-02At Loss
2021-10-01At Loss 2021-07-30At Loss
2021-09-30At Loss 2021-07-29At Loss
2021-09-29At Loss 2021-07-28At Loss
2021-09-28At Loss 2021-07-27At Loss
2021-09-27At Loss 2021-07-26At Loss
2021-09-24At Loss 2021-07-23At Loss
2021-09-23At Loss 2021-07-22At Loss
2021-09-22At Loss 2021-07-21At Loss
2021-09-21At Loss 2021-07-20At Loss
2021-09-20At Loss 2021-07-19At Loss
2021-09-17At Loss 2021-07-16At Loss
2021-09-16At Loss 2021-07-15At Loss
2021-09-15At Loss 2021-07-14At Loss
2021-09-14At Loss 2021-07-13At Loss
2021-09-13At Loss 2021-07-12At Loss
2021-09-10At Loss 2021-07-09At Loss
2021-09-09At Loss 2021-07-08At Loss
2021-09-08At Loss 2021-07-07At Loss
2021-09-07At Loss 2021-07-06At Loss
2021-09-06At Loss 2021-07-05At Loss
2021-09-03At Loss 2021-07-02At Loss
2021-09-02At Loss 2021-07-01At Loss
2021-09-01At Loss 2021-06-30At Loss
2021-08-31At Loss 2021-06-29At Loss
2021-08-30At Loss 2021-06-28At Loss
2021-08-27At Loss 2021-06-25At Loss
2021-08-26At Loss 2021-06-24At Loss
2021-08-25At Loss 2021-06-23At Loss

Opiant Pharmaceuticals PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Opiant Pharmaceuticals Inc logo

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325412 SIC : 2834
Traded in other countries / regions
Address
233 Wilshire Blvd, Suite 280, Santa Monica, CA, USA, 90401
Website
https://www.opiant.com
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.